EGFR and non-small cell lung carcinoma: However, NK cell subsets should be studied in larger cohorts of NSCLC patient samples including those with EGFR and ALK alterations, and NK cell therapies should be tested in pre-clinical models of these specific genomic subtypes of NSCLC.